ANDA 210992, held by Granules India. Methylphenidate Hydrochloride.
As of Nov 19, 2026, ANDA 210992 (Methylphenidate Hydrochloride), held by Granules India, was first approved by FDA on Nov 21, 2018, with 2 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride extended-release tablets in adults and pediatric patients 6 years and older are indicated for the treatment of: Attention deficit hyperactivity disorder (ADHD) Narcolepsy Limitations of Use The use of methylphenidate hydrochloride extended-release tablets are not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2018 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride10MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Mar 25, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 21, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters